The board (the "Board") of directors (the "Directors") of JW (Cayman) Therapeutics Co. Ltd. announced that, the National Medical Products Administration (the "NMPA") of China has approved the New Drug Application ("NDA") for the Company's anti-CD19 autologous chimeric antigen receptor T ("CAR-T") cell immunotherapy product relmacabtagene autoleucel injection ("relma-cel"), R&D code: JWCAR029) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma ("r/r LBCL") after two or more lines of systemic therapy. Relma-cel is the first CAR-T product approved as a Category 1 biologics product in China, and sixth approved CAR-T product globally. Relma-cel, JW Therapeutics' first CAR-T product, was independently developed based on a CAR-T cell process platform of Juno Therapeutics (a Bristol Myers Squibb company) to meet the needs of the Chinese market. Currently, it is the only approved CAR-T product in China that has been simultaneously included in the National Significant New Drug Development Program, granted priority review (for relma-cel as a treatment of r/r LBCL) and breakthrough therapy designations (for relma-cel as a treatment of follicular lymphoma). To date, over 100 patients have been dosed with relma-cel in clinical studies, making relma-cel the most studied anti-CD19 CAR-T product in China. This approval is based on the results of a single-arm, multi-center, pivotal study ("RELIANCE study") to evaluate the efficacy and safety of relma-cel in patients with r/r LBCL in China. RELIANCE study results show that relma-cel demonstrated high rates of durable disease response and low rates of CAR-T associated toxicities, and may provide a best-in-class CAR-T therapy profile.